China Stone Pharmaceutical Group (02005.HK): Obtained the drug production registration approvals for hydrochloride decenadilone tablets (400mg) and methylsulfonamide bezethol injections (0.1g) from the National Medical Products Administration.

Zhijing Financial News APP, Sis Pharmaceuticals Group (02005.HK) announced that the group has obtained the drug production registration approval from the China National Medical Products Administration for the hydrochloride propafenone tablets (400mg), which belong to the category 4 of chemical drugs and are considered to have passed the consistency evaluation. Hydrochloride propafenone tablets are a new type of antiarrhythmic drug, mainly used for patients with paroxysmal or persistent atrial fibrillation history, to reduce the risk of hospitalization due to atrial fibrillation. As stated in the announcement dated December 16, 2024, the group's hydrochloride propafenone active pharmaceutical ingredient has been approved by the National Medical Products Administration to be registered as an active pharmaceutical ingredient for use in marketed preparations.